CTRI/2024/05/067236
Not yet recruiting
未知
A preliminary investigation of the safety and effectiveness of oral probiotics supplementation for reducing the risk of kidney stone in adults with recurrent kidney stone colic or acute episode of colicky pain: An open-label, single-arm, prospective, interventional, proof-of-science study. - Nil
Meteoric Biopharmaceuticals Pvt. Ltd.0 sites0 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Meteoric Biopharmaceuticals Pvt. Ltd.
- Status
- Not yet recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.The subject is an adult aged between 18 to 55 years old.
- •2\.The subject has a history of recurrent kidney stone colic or acute episode of colicky pain on clinical examination by Physician.
- •3\.The subject is willing to provide written informed consent and comply with study procedures, including overnight stay for 24 hours at the study centre during both visits.
- •4\.The subject is willing to abide by the study protocol and restrictions, including abstaining from using any other oral or topical treatments for kidney stone colic during the study period.
- •5\.The subject is in a stable medical condition, not requiring immediate intervention or hospitalization.
- •6\.If the subject is female, she is willing to use a highly effective method of contraception throughout the clinical investigation.
- •a.Females of childbearing potential must practice and maintain an established method of birth control (e.g., IUD, hormonal implant device/injection, birth control pills, diaphragm, condoms with spermicide, partner vasectomy, or abstinence).
- •b.Non\-childbearing potential females who are surgically sterile, post\-menopausal for at least 1 year, or have had a tubal ligation, must have been using hormonal contraception for at least 6 months and agree to continue using the same contraception for the study duration.
Exclusion Criteria
- •1 Subject has a history of severe renal impairment or chronic kidney disease.
- •2 Subject is pregnant/lactating, or is planning on become pregnant during the course of the study.
- •3 Subject has presence of significant medical or psychiatric conditions that may interfere with study participation or interpretation of results.
- •4 Subject has a history of substance abuse or dependence.
- •5 Subject has severe systemic complications of viral infections, cardiovascular disorders, neurological disorders, renal disorders, or autoimmune disorders.
- •6 Subject has participated in clinical studies or received any investigational agent in the previous 30 days.
- •7 Subject has any condition that, in the judgement of investigator, would compromise the safety of subject or study integrity.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
A clinical study to determine the safety and efficacy of an Oral Probiotic supplementation to improve Bacterial Vaginosis in females.Health Condition 1: N768- Other specified inflammation of vagina and vulvaCTRI/2024/05/067530Meteoric Biopharmaceuticals Pvt. Ltd.
Recruiting
Not Applicable
Preliminary study for examining the safety and efficacy of fecal transplantation therapy in refractory intestinal diseasesrefractory intestinal diseasesJPRN-UMIN000026363agoya University20
Recruiting
Phase 1
Safety and Efficacy of MagSense Human Epidermal Growth Factor Receptor 2 (HER2) Test Reagent in Breast Cancer Lymph Node Magnetic Reasonance Imaging (MRI) and Magnetic Relaxometry (MRX).Breast CancerCancer - BreastACTRN12621000126819Imagion Biosystems, Ltd30
Recruiting
Not Applicable
A phase 1 Study to Evaluate the Safety and Feasibility of Intraoperative Detection of Clear Cell Renal Cell Carcinoma Using Indium-111-DOTA-girentuximab-IRDye800CWclear cell renal cell carcinomaKidney cancer100383641003843010038365NL-OMON43587niversitair Medisch Centrum Sint Radboud22
Completed
Not Applicable
A Phase I Study Assessing the Safety and Performance of SGM-101, a Fluorochrome-Labeled Anti-Carcinoembryonic Antigen Monoclonal Antibody for the Intraoperative Detection of Neoplastic Lesions in Patients with Cancer of the Colorectum or PancreasNL-OMON47359Surgimab85